New antib combo shows promise in lung cancer fight
NCT ID NCT05247684
First seen Mar 08, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests a new drug called AK112, given alone or with chemotherapy, before and after surgery for people with early-stage non-small cell lung cancer that can be removed. The goal is to see if it helps shrink tumors before surgery and prevent cancer from coming back after. About 90 adults aged 18-75 with stage II-IIIB lung cancer are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.